Episode
Why Private Equity Is Buying Up Independent Pharmacies
- Published
- Jun 23, 2026
- Duration seconds
- 520
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-buyout-show-with-fexingo-private-equity-roll-ups-and-business-acquisitions-7871630/episodes/why-private-equity-is-buying-up-independent-pharmacies/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-buyout-show-with-fexingo-private-equity-roll-ups-and-business-acquisitions-7871630/why-private-equity-is-buying-up-independent-pharmacies.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Episode 69 of The Buyout Show with Fexingo. Lucas and Luna examine the wave of private equity acquisitions of independent pharmacies, focusing on the specific strategy of roll-ups like the one led by Oak Street Health's former executives. They discuss the economics: how a single independent pharmacy generates roughly $3-5 million in revenue but only 8-12% EBITDA margins, and how consolidation into a 50-plus location entity can boost margins to 20% through centralized purchasing and back-office efficiencies. They also touch on the regulatory risks, including the FTC's recent scrutiny of pharmacy benefit manager practices. Hosts: Lucas and Luna. #PrivateEquity #Pharmacies #RollUps #IndependentPharmacy #OakStreetHealth #EBITDA #FTC #PBMs #PharmacyBenefitManagers #Consolidation #Healthcare #MergersAndAcquisitions #LBO #BusinessStrategy #FexingoBusiness #BusinessPodcast #TheBuyoutShow #RetailPharmacy Keep every episode free: buymeacoffee.com/fexingo